Sacituzumab govitecan (SG) with bevacizumab for the treatment of brain metastases from non-small cell lung cancer (NSCLC)

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Academisch Ziekenhuis Maastricht

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Respiratory Tract Diseases [C08], Diseases [C] - Neoplasms [C04]

Trial duration

10 Jul 2025 → ongoing

Decision date (initial)

2025-01-21

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

MUMC and Gilead

External identifiers

EU CT number

2024-514066-40-00

ClinicalTrials.gov

NCT06401824

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety, Therapy

To evaluate the BM ORR of SG plus bevacizumab measured with the Response Assessment in Neuro-Oncology (RANO)-BM criteria.

Secondary objectives 9

1. To evaluate the BM ORR of SG plus bevacizumab measured with the Response Assessment in Neuro-Oncology (RANO)-BM criteria, with additional criteria for potential pseudo response due to bevacizumab
2. To evaluate the BM DCR and median CNS PFS of SG plus bevacizumab according to RANO-BM
3. To evaluate the extracranial ORR and DCR of SG plus bevacizumab according to RECIST 1.1
4. To evaluate the extracranial PFS of SG plus bevacizumab according to RECIST 1.1
5. To evaluate the overall PFS of SG plus bevacizumab (RANO-BM for BM, RECIST 1.1 for extracranial lesions)
6. To evaluate the median OS of SG plus bevacizumab
7. To evaluate the safety of SG plus bevacizumab according to CTCAE v5.0 criteria Exploratory Objectives
8. To explore the correlation of UGT1A1 genotype with tolerability of SG plus bevacizumab
9. To explore the correlation of UGT11 genotype with efficacy of SG plus bevacizumab

Conditions and MedDRA coding

Patients with metastatic non-squamous NSCLC pre-treated with platinum-doublet chemotherapy and ICI (for those with targetable oncogenic drivers, pretreated with at least one tyrosine kinase inhibitor and platinum-doublet chemotherapy), and active BM, defined as asymptomatic untreated or unequivocally progressive after local treatment

Study design 1 period

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 14

1. 1. Signed informed consent must be obtained prior to participation in the study.
2. 2. Participant is an adult ≥ 18 years of age at the time of informed consent.
3. 3. ECOG performance status ≤1.
4. 4. Estimated life expectancy of 12 weeks or more.
5. 5. Pathology proven metastatic non-squamous NSCLC
6. 6. For those without an actionable oncogenic driver: progression on immunotherapy and/or platinum-doublet chemotherapy (concurrent or sequential, in any order). If contra-indication for immunotherapy: progression on platinum-doublet chemotherapy.
7. 7. For those with an actionable oncogenic driver: progression on targeted therapy and platinum-doublet chemotherapy. For the latter group, previous ICI is allowed but not mandatory.
8. 8. BM not in eloquent area (all patients have at least to be discussed with a neurologist, and preferably they are discussed in the local neuro-oncology MDT).
9. 9. Maximum BM size 2 cm in longest diameter (for each BM).
10. 10. At least one untreated brain metastasis ≥ 5mm: a. Patients with largest measurable intracranial lesion ≥5 mm but <10 mm may be allowed to enroll upon agreement with the principal investigator (for patients with target lesions of ≥ 5mm but <10 mm, 1.5 mm slice thickness brain MRI is required). b. Prior local treatment is permissible provided unequivocal progression in the lesion has since occurred (discussed in neuro-oncology MDT) or if new lesions have occurred. c. For at least 7 days prior to first dose of SG and bevacizumab in this study: Patient must be asymptomatic from CNS metastases and on a stable dose of corticosteroids, with a maximum of 4 mg dexamethasone/day. Anti-epileptic dose should also be stable for 7 days.
11. 11. Participant must have recovered from all toxicities related to prior treatments to grade ≤ 1 (CTCAE v 5.0). Exception to this criterion are alopecia and neuropathy of any grades.
12. 12. Adequate organ function including the following laboratory values at the screening visit: · Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (without growth factor support), · Platelets ≥ 100 x 109/L (without growth factor support), · Hemoglobin (Hb) ≥ 6 mmol/l (= 9 g/dl) (7 days without transfusions or growth factor support), · Aspartate transaminase (AST) ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases · Alanine transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases · Serum albumin > 3 g/dL · Total bilirubin ≤ 1.5 ULN, · Creatinine clearance ≥ 30 mL/min by calculation using Cockcroft-Gault formula or based on 24-hour urine sample assessment.
13. 13. Participant is capable of following instructions regarding study treatment administration, and must be able to communicate with the Investigator and comply with the requirements of the study procedures.
14. 14. Negative serum or urine pregnancy test within 7 days prior to study treatment in women with childbearing potential. Patient must be willing to use effective methods of contraception. Female patients must be postmenopausal, surgically sterile, or they must agree to use a physical barrier method of contraception in addition to either an intrauterine device or hormonal contraception until at least 4 months after termination of study drug.

Exclusion criteria 19

1. 1. Leptomeningeal metastasis (based on MRI or CSF cytology, if strong suspicion despite negative MRI, CSF analysis should be done).
2. 10. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn’s disease) or GI perforation within 6 months of enrolment.
3. 11. Have active serious infection requiring antibiotics.
4. 12. Have known history of HIV-1 or 2 (or positive HIV-1/2 antibody, if done at screening) with detectable viral load OR taking medications that may interfere with SN-38 metabolism.
5. 13. Have known active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.
6. 14. Have other concurrent medical or psychiatric conditions that, in the investigator’s opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
7. 15. Any medical condition that, in the investigator’s or sponsor’s opinion, poses an undue risk to the patient’s participation in the study
8. 16. Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of first dose of study drug.
9. 17. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary embolism within 1 months of enrolment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, uncontrolled pleural effusion, etc.); any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjogren syndrome, sarcoidosis, etc.); or prior pneumonectomy.
10. 18. Contra-indications specific to bevacizumab a. Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg). Anti-hypertensive therapy to achieve these parameters is allowable. b. Prior history of hypertensive crisis or hypertensive encephalopathy. c. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to start of treatment. d. History of hemoptysis (≥ one-half teaspoon of bright red blood per episode) within 1 month prior to start of treatment. e. Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation). f. Current or recent (within 10 days of start of treatment) use of aspirin (> 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol. g. Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for > 2 weeks prior to start of treatment. The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least 2 weeks prior to start of treatment. h. Prophylactic anticoagulation for the patency of venous access devices is allowed, provided the activity of the agent results in an INR < 1.5 × ULN and aPTT is within normal limits within 14 days prior to start of treatment. i. Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg/day) is permitted. j. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab. k. History of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to start of treatment. l. Clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding. m. Evidence of abdominal free air not explained by paracentesis or recent surgical procedure. n. Serious, non-healing wound, active ulcer, or untreated bone fracture. o. Proteinuria, as demonstrated by urine dipstick or > 1.0 g of protein in a 24-hour urine collection. All patients with ≥ 2+ protein on dipstick urinalysis at baseline must undergo a 24-hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours. p. Clear tumour infiltration into the thoracic great vessels is seen on imaging. q. Clear cavitation of pulmonary lesions is seen on imaging.
11. 2. Previous treatment with TROP2 inhibitor or angiogenesis inhibitor.
12. 3. Known hypersensitivity to the study drugs, its metabolites, or formulation excipient.
13. 4. Positive serum pregnancy test or women who are breastfeeding.
14. 5. Contra-indication for MRI.
15. 6. History of allogeneic bone marrow or solid organ transplant.
16. 7. Have had a prior anticancer biologic agent (ADC, ICI) within 4 weeks prior to enrolment or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry. a. Note: Patients participating in observational studies are eligible.
17. 8. Have an active second malignancy. Note: patients with a history of malignancy that has been treated completely, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumours with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll.
18. 9. Met any of the following criteria for cardiac disease: a. Myocardial infarction or unstable angina pectoris within 6 months of enrollment. b. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation. c. New York Heart Association (NYHA) class III or greater congestive heart failure or left ventricular ejection fraction of < 40%.
19. 10. Known hypersensitivity to iodinated contrast agents.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. BM ORR (RANO-BM). This will be evaluated with MRI brain after six weeks of treatment and thereafter every six weeks. Confirmed BM ORR according to RANO-BM will be measured at 12 weeks.

Secondary endpoints 8

1. All imaging related endpoints will be measured with MRI brain for BM related outcomes and CT chest and upper abdomen for extracranial related outcomes after six weeks of treatment and thereafter every six weeks
2. BM ORR (RANO-BM), with additional criteria for potential pseudo response due to bevacizumab
3. BM DCR (RANO-BM), median CNS PFS (RANO-BM)
4. Extracranial ORR and DCR (RECIST 1.1).
5. Median extracranial PFS (based on RECIST 1.1)
6. Median overall PFS (based on RANO-BM for BM and RECIST 1.1 for extracranial lesions)
7. Median OS
8. Safety, evaluated with CTCAE v5.0 criteria during every visit

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 3

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Academisch Ziekenhuis Maastricht

Sponsor organisation

Academisch Ziekenhuis Maastricht

Address

P Debyelaan 25

City

Maastricht

Postcode

6229 HX

Country

Netherlands

Scientific contact point

Organisation

Academisch Ziekenhuis Maastricht

Contact name

Lizza Hendriks

Public contact point

Organisation

Academisch Ziekenhuis Maastricht

Contact name

Lizza Hendriks

Locations

1 EU/EEA country · 3 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 7 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

3 submissions — initial application plus substantial / non-substantial modifications